4 completed, 3 terminated, 2 active not recruiting, 1 not yet recruiting. 8 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 4, Active not recruiting 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 7 | Terminated 3, Active not recruiting 2, Completed 2 |
Follow Recurrent Anaplastic Large Cell Lymphoma: new trials by email Literature Review of Recurrent Anaplastic Large Cell Lymphoma trials Research Report on Recurrent Anaplastic Large Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Parsaclisib, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Walter Hanel | 5 | 2021-09-01 | 2025-01-17 |
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-04 | 2026-05-26 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-11-14 | 2026-09-30 |
| Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Laboratory Biomarker Analysis, Nivolumab - Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma | Phase 2 | Terminated | Mayo Clinic | 12 | 2017-05-17 | 2020-04-21 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 99 | 2017-04-04 | 2026-06-10 |
| Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL Onalespib - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2016-04-04 | 2022-09-13 |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 22 | 2012-10-29 | 2018-09-19 |
| Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 46 | 2010-05-19 | 2023-01-23 |
| Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Anaplastic Large Cell Lymphoma | Phase 1 / Phase 2 | Completed | University of Nebraska | 74 | 2009-11-12 | 2023-10-10 |
Lymphoma, Large-Cell, Anaplastic (11) · Lymphoma, T-Cell (8) · Mycosis Fungoides (6) · Immunoblastic Lymphadenopathy (5) · Enteropathy-Associated T-Cell Lymphoma (4) · Lymphoma, Mantle-Cell (3) · Lymphoma, T-Cell, Cutaneous (3) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (2) · Subcutaneous panniculitis-like T-cell lymphoma (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Burkitt Lymphoma (1)
Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoma (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Lymphoma, Non-Hodgkin (10) · Lymphadenopathy (5) · Lymphoma, T-Cell, Cutaneous (4) · Hematologic Diseases (3) · Leukemia (3) · Lymphoma, T-Cell (3) · Blood Protein Disorders (2)
Cyclophosphamide (3) · Depsipeptides (3) · Lactones (3) · romidepsin (3) · 10-propargyl-10-deazaaminopterin (2) · Etoposide (2) · Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · Specimen Handling (2) · fludarabine phosphate (2) · pembrolizumab (2) · (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1) · AFM13 (1) · Azacitidine (1) · Biopsy (1)
M.D. Anderson Cancer Center (3) · City of Hope Medical Center (2) · Mayo Clinic (2) · Fred Hutchinson Cancer Center (1) · National Cancer Institute (NCI) (1) · University of Nebraska (1) · Walter Hanel (1)
United States (11)
Alex F Herrera (1) · Caron A Jacobson (1) · Christina Poh (1) · Joselle Cook, M.B.B.S. (1) · Julie Vose, MD, MBA (1) · Michelle Fanale (1) · Nora Bennani, M.D. (1) · Rachel B. Salit (1) · Stephen Ansell (1) · Swaminathan P Iyer, MD (1) · Walter Hanel, MD, PhD (1) · Yago L Nieto (1)
PMID 23834234, PMID 29622656, PMID 35175355, PMID 35750419, PMID 36898933, PMID 40186077
P30CA015083 (1), P30CA016672 (1), P30CA033572 (1), P30CA036727 (1), P50CA186781 (1), R01CA262613 (1), UM1CA186690 (1), UM1CA186709 (1)